Search

everythinglearnresearchcommunity

for

Search:↓

Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.

The Shumin device with doxycycline is more effective for rosacea than red light therapy.

Prolactin contributes to hair loss by promoting hair follicle shrinkage and cell death.

Using a protocol with LH improves pregnancy rates in patients with low ovarian reserve.

Male sperm disorders significantly contribute to infertility.

Kinematic alignment in knee surgery often requires smaller femoral components than mechanical alignment.

Pre-surgical embolization and a two-stage resection improve outcomes for rare sacral tumors.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Some alopecia treatments might help treat COVID-19, but more research is needed.

Upadacitinib effectively treats psoriasis and lichen planus together.

STS01 1% effectively promotes hair regrowth with minimal side effects.

Severe Hidradenitis Suppurativa increases missed and unproductive workdays.

Alopecia areata may be treated by using EGCG to balance immune cells and reduce inflammation.

K_ATP channel gene mutations are linked to heart diseases, but more research is needed to understand the connection and treatment potential.

Glutamine metabolism affects hair stem cell maintenance and their ability to change back to stem cells.

Drug repurposing is a faster, cheaper way to develop new treatments using existing drugs.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

Abrocitinib may effectively treat stubborn alopecia universalis.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Ruxolitinib can cause a delayed skin reaction on the nose.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.

JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.